HLS Therapeutics Inc. (TSX:HLS)

HLS Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	11.72	17.46	21.95	20.72	21.18
Cash & Short-Term Investments	11.72	17.46	21.95	20.72	21.18
Cash Growth	-32.84%	-20.48%	5.93%	-2.15%	2.75%
Accounts Receivable	7.86	7.45	10.61	11	11.51
Inventory	8.14	9.06	9.53	8.9	8.93
Other Current Assets	1.37	1.43	2	3.75	2.14
Total Current Assets	29.09	35.4	44.1	44.37	43.75
Net Property, Plant & Equipment	1.34	1	0.97	1.13	1.57
Other Intangible Assets	105.63	122.12	162.34	195.02	229.18
Other Long-Term Assets	1.47	1.39	1.66	1.13	1.4
Total Assets	137.53	159.9	209.06	241.65	275.91
Accounts Payable	10.44	8.71	14.11	12.79	10.6
Short-Term Debt	4.82	5.32	6.88	15.47	13.51
Other Current Liabilities	10.87	8.52	5.71	2.93	3.57
Total Current Liabilities	26.12	22.55	26.69	31.19	27.67
Long-Term Debt	46.68	61.94	84.23	84.58	86.84
Other Long-Term Liabilities	3.06	4.07	0.44	0.57	0.65
Total Long-Term Liabilities	49.74	66.02	84.68	85.14	87.5
Total Liabilities	75.86	88.56	111.36	116.33	115.17
Common Stock	256.34	260.6	262.13	265.21	265.92
Additional Paid-in Capital	16.16	15.14	13.87	13.82	11.72
Accumulated Other Comprehensive Income	-6.68	-10.21	-2.84	-5.26	2.96
Retained Earnings	-204.15	-194.18	-175.46	-148.45	-119.86
Shareholders' Equity	61.67	71.34	97.7	125.32	160.74
Total Liabilities & Equity	137.53	159.9	209.06	241.65	275.91
Total Debt	51.5	67.26	91.11	100.05	100.35
Net Cash (Debt)	-39.77	-49.81	-69.16	-79.33	-79.17
Net Cash Per Share	-1.26	-1.56	-2.14	-2.45	-2.46
Book Value	61.67	71.34	97.7	125.32	160.74
Book Value Per Share	1.96	2.24	3.03	3.86	4.99
Tangible Book Value	-43.96	-50.78	-64.65	-69.7	-68.45
Tangible Book Value Per Share	-1.39	-1.59	-2.00	-2.15	-2.13

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.